Nature Communications (Dec 2021)
Androgen receptor and MYC equilibration centralizes on developmental super-enhancer
- Haiyang Guo,
- Yiming Wu,
- Mannan Nouri,
- Sandor Spisak,
- Joshua W. Russo,
- Adam G. Sowalsky,
- Mark M. Pomerantz,
- Zhao Wei,
- Keegan Korthauer,
- Ji-Heui Seo,
- Liyang Wang,
- Seiji Arai,
- Matthew L. Freedman,
- Housheng Hansen He,
- Shaoyong Chen,
- Steven P. Balk
Affiliations
- Haiyang Guo
- Department of Clinical Laboratory, The Second Hospital, Cheeloo College of Medicine, Shandong University
- Yiming Wu
- Hematology-Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School
- Mannan Nouri
- Hematology-Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School
- Sandor Spisak
- Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School
- Joshua W. Russo
- Hematology-Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School
- Adam G. Sowalsky
- Laboratory of Genitourinary Cancer Pathogenesis, National Cancer Institute, National Institutes of Health
- Mark M. Pomerantz
- Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School
- Zhao Wei
- Department of Clinical Laboratory, Qilu Hospital of Shandong University
- Keegan Korthauer
- Department of Statistics, University of British Columbia
- Ji-Heui Seo
- Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School
- Liyang Wang
- Hematology-Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School
- Seiji Arai
- Hematology-Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School
- Matthew L. Freedman
- Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School
- Housheng Hansen He
- Department of Medical Biophysics, University of Toronto
- Shaoyong Chen
- Hematology-Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School
- Steven P. Balk
- Hematology-Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School
- DOI
- https://doi.org/10.1038/s41467-021-27077-y
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 18
Abstract
Androgen receptor in prostate cancer (PCa) transcriptionally represses multiple genes including MYC. Here, the authors suggest that increased MYC in response to androgen deprivation contributes to castration-resistant PCa, while decreased MYC may contribute to responses to supraphysiological androgen therapy.
